Current view of neoadjuvant chemotherapy in primarily
resectable pancreatic adenocarcinoma

J 2021

Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma

EID, Michal, Lenka OSTŘÍŽKOVÁ, Lumír KUNOVSKÝ, Dagmar BRANČÍKOVÁ, Zdeněk KALA et. al.

Basic information

Original name

Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma

Authors

EID, Michal (203 Czech Republic, guarantor, belonging to the institution), Lenka OSTŘÍŽKOVÁ (203 Czech Republic, belonging to the institution), Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Dagmar BRANČÍKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Jan HLAVSA (203 Czech Republic, belonging to the institution), Pavel JANEČEK (203 Czech Republic), Ivana KOSÍKOVÁ (203 Czech Republic, belonging to the institution), Monika BLAŽKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Neoplasma, Bratislava, Slovak Academy of Sciences, 2021, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.409

RIV identification code

RIV/00216224:14110/21:00121810

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/neo_2020_200408N372

UT WoS

000661880800001

Keywords in English

pancreas; carcinoma; resectable; neoadjuvant; treatment

Abstract

V originále

Pancreatic ductal adenocarcinoma (PDAC) is now the 11th most common cancer and in 2018 there were 458,918 new cases worldwide. In the Czech Republic, a total of 2,173 patients were diagnosed in 2015, ranking the second in incidence worldwide. In contrast to other malignancies, recent research has not brought any major breakthrough in the treatment of PDAC and hence the prognosis remains very serious. Radical resection is the only curative approach, but after the initiation of the standard pathological evaluation of the resected tissue, according to the Leeds protocol, 80% of the resections are R1 (resections with microscopically positive margins). The results of studies in patients with borderline resectable or locally advanced PDAC prefer neoadjuvant chemotherapy or chemoradiotherapy. This approach leads to a higher number of radical R0 resections and better survival. For neoadjuvant treatment in patients with primarily resectable PDAC, most results come from retrospective analysis or phase II trials. However, recently, data from three randomized clinical trials with neoadjuvant therapy for resectable PDAC were presented. These results support the use of chemotherapy or chemoradiotherapy prior to surgery. In the trials published to date, there are differences in chemotherapeutic regimens, cytostatic doses, and the definition of resectability. Thus, up-front resection with adjuvant chemotherapy is still the standard of care and a well-designed randomized trial using neoadjuvant therapy is now necessary.

Citovat

EID, Michal, Lenka OSTŘÍŽKOVÁ, Lumír KUNOVSKÝ, Dagmar BRANČÍKOVÁ, Zdeněk KALA, Jan HLAVSA, Pavel JANEČEK, Ivana KOSÍKOVÁ, Monika BLAŽKOVÁ, Ondřej SLABÝ and Jiří MAYER. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. Neoplasma. Bratislava: Slovak Academy of Sciences, 2021, vol. 68, No 1, p. 1-9. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2020_200408N372.

@article{1777417,
   author = {Eid, Michal and Ostřížková, Lenka and Kunovský, Lumír and Brančíková, Dagmar and Kala, Zdeněk and Hlavsa, Jan and Janeček, Pavel and Kosíková, Ivana and Blažková, Monika and Slabý, Ondřej and Mayer, Jiří},
   article_location = {Bratislava},
   article_number = {1},
   doi = {http://dx.doi.org/10.4149/neo_2020_200408N372},
   keywords = {pancreas; carcinoma; resectable; neoadjuvant; treatment},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6905&category_id=172&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {68},
   year = {2021}
}

TY  - JOUR
ID  - 1777417
AU  - Eid, Michal - Ostřížková, Lenka - Kunovský, Lumír - Brančíková, Dagmar - Kala, Zdeněk - Hlavsa, Jan - Janeček, Pavel - Kosíková, Ivana - Blažková, Monika - Slabý, Ondřej - Mayer, Jiří
PY  - 2021
TI  - Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma
JF  - Neoplasma
VL  - 68
IS  - 1
SP  - 1-9
EP  - 1-9
PB  - Slovak Academy of Sciences
SN  - 00282685
KW  - pancreas
KW  - carcinoma
KW  - resectable
KW  - neoadjuvant
KW  - treatment
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6905&category_id=172&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - Pancreatic ductal adenocarcinoma (PDAC) is now the 11th most common cancer and in 2018 there were 458,918 new cases worldwide. In the Czech Republic, a total of 2,173 patients were diagnosed in 2015, ranking the second in incidence worldwide. In contrast to other malignancies, recent research has not brought any major breakthrough in the treatment of PDAC and hence the prognosis remains very serious. Radical resection is the only curative approach, but after the initiation of the standard pathological evaluation of the resected tissue, according to the Leeds protocol, 80% of the resections are R1 (resections with microscopically positive margins). The results of studies in patients with borderline resectable or locally advanced PDAC prefer neoadjuvant chemotherapy or chemoradiotherapy. This approach leads to a higher number of radical R0 resections and better survival. For neoadjuvant treatment in patients with primarily resectable PDAC, most results come from retrospective analysis or phase II trials. However, recently, data from three randomized clinical trials with neoadjuvant therapy for resectable PDAC were presented. These results support the use of chemotherapy or chemoradiotherapy prior to surgery. In the trials published to date, there are differences in chemotherapeutic regimens, cytostatic doses, and the definition of resectability. Thus, up-front resection with adjuvant chemotherapy is still the standard of care and a well-designed randomized trial using neoadjuvant therapy is now necessary.
ER  -

EID, Michal, Lenka OSTŘÍŽKOVÁ, Lumír KUNOVSKÝ, Dagmar BRANČÍKOVÁ, Zdeněk KALA, Jan HLAVSA, Pavel JANEČEK, Ivana KOSÍKOVÁ, Monika BLAŽKOVÁ, Ondřej SLABÝ and Jiří MAYER. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. \textit{Neoplasma}. Bratislava: Slovak Academy of Sciences, 2021, vol.~68, No~1, p.~1-9. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2020\_{}200408N372.

Detailed Information on Publication Record